Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

View Full Paper
Ask AI
Bookmark
Share

Authors

FZFatima Tuz ZahraDDDaniel DeAvilaCBCeleste Bello

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows progression-free survival of 3.1 months in outpatient B-NHL, indicating treatment efficacy in high-risk patients.

Key Points

  • B-cell lymphoma treatments resulted in overall survival of 9.3 months, with outpatient settings showing better outcomes.
  • Median progression-free survival for the whole cohort was 3.1 months, with 1-year progression-free survival at 26%.
  • Observational analysis revealed significant associations between trial non-eligibility and poor survival in treated patients.
  • Outpatient management may provide feasible alternatives for high-risk B-cell lymphoma patients not suitable for trials.

Cite This Study

Zahra et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db8dhttps://doi.org/10.1182/blood-2025-2767
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab2025
  2. 2Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study2025 · 1 citations
  3. 3Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma2025
  4. 4Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.2025
  5. 5Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need2025